53078-85-6

Basic information

• Product Name: 2-Bromo-5-methylbenzenamine
• Synonyms: 2-BROMO-5-METHYLANILINE;2-bromo-5-methylbenzenamine;2-BROMO-5-METHYL-PHENYLAMINE;CHEMPACIFIC 39968;2-Bromo-5-methylbenz;2-BroMo-5-Methylanline;2-Bromo-5-methylaniline 98%;3-Amino-4-bromotoluene, 6-Bromo-m-toluidine
• CAS NO: 53078-85-6
• Molecular Formula: C₇H₈BrN
• Molecular Weight: 186.05
• Product Categories: Amines;C7;Nitrogen Compounds
• Mol File: 53078-85-6.mol
• Article Data: 20

Chemical Properties

• Melting Point: 46°C
• Boiling Point: 130°C/16mmHg(lit.)
• Flash Point: 110 °C
• Appearance: /Solid
• Density: 1.486 g/mL at 25 °C
• Vapor Pressure: 0.0249mmHg at 25°C
• Refractive Index: n20/D 1.603
• Storage Temp.: 2-8°C
• PKA: 2.66±0.10(Predicted)
• CAS DataBase Reference: 2-Bromo-5-methylbenzenamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-5-methylbenzenamine(53078-85-6)
• EPA Substance Registry System: 2-Bromo-5-methylbenzenamine(53078-85-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38-20/21/22
• Safety Statements: 9-26-36/37-60
• RIDADR: 2811
• WGK Germany: 3
• HazardClass: 6.1
• Hazardous Substances Data: 53078-85-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H8BrN/c1-5-2-3-6(8)7(9)4-5/h2-4H,9H2,1H3

Upstream product

• 5326-34-1 4-Bromo-3-nitrotoluene 
• 108-44-1 1-amino-3-methylbenzene 
• 7439-89-6 iron 
• 60956-26-5 4-bromo-2-nitrotoluene 
• 89-62-3 4-methyl-2-nitroaniline 
• 612-45-3 4-methyl-2-nitroacetanilide 
• 7647-01-0 hydrogenchloride 
• 126759-48-6 N-(2-bromo-5-methylphenyl)acetamide 

Downstream Products

• 112671-45-1 ethyl 2-bromo-5-methylcarbanilate 
• 823803-51-6 8-bromo-5-methylquinoline 
• 149-30-4 2-Mercaptobenzothiazole 
• 21303-50-4 2-mercapto-5-methyl benzothiazole 
• 2305-36-4 4-methylanthranilic acid 
• 143879-61-2 5-methyl-2-vinylaniline 
• 126759-48-6 N-(2-bromo-5-methylphenyl)acetamide 
• 7420-86-2 5-methyl-2-phenyl-1,3-benzoxazole 
• 2585-18-4 4,7-dimethyl-1,2-dihydroquinolin-2-one 
• 1186638-13-0 3-chloro-5-(4-propoxyphenethyl)picolinonitrile 
• 1155264-26-8 C₂HF₃O₂*C₁₀H₁₀BNO₂ 

Relevant articles and documents

Superior activity and selectivity of heterogenized cobalt catalysts for hydrogenation of nitroarenes

The development of improved catalysts for highly selective hydrogenation of nitroarenes is described. For this purpose Co nanoparticles were supported on ordered mesoporous carbon CMK-3 and characterized in detail. The optimal CMK-3-CoPc catalyst exhibits excellent hydrogenation activity for several (hetero)aromatic nitro compounds and yielded the corresponding anilines under mild conditions (40 °C, 20 bar H2).

A capping agent dissolution method for the synthesis of metal nanosponges and their catalytic activity towards nitroarene reduction under mild conditions

We report a general strategy for the synthesis of metal nanosponges (M = Ag, Au, Pt, Pd, and Cu) using a capping agent dissolution method where addition of water to the M@BNHx nanocomposite affords the metal nanosponges. The B-H bond of the BNHx polymer gets hydrolysed upon addition of water and produces hydrogen gas bubbles which act as dynamic templates leading to the formation of nanosponges. The rate of B-H bond hydrolysis has a direct impact on the final nanostructure of the materials. The metal nanosponges were characterized using powder XRD, electron microscopy, XPS, and BET surface area analyzer techniques. The porous structure of these nanosponges offers a large number of accessible surface sites for catalytic reactions. The catalytic activity of these metal nanosponges has been demonstrated for the reduction of 4-nitrophenol where palladium exhibits the highest catalytic activity (k = 0.314 min?1). The catalytic activity of palladium nanosponge was verified for the tandem dehydrogenation of ammonia borane and the hydrogenation of nitroarenes to arylamines in methanol at room temperature. The reduction of various substituted nitroarenes was proven to be functional group tolerant except for a few halogenated nitroarenes (X = Br and I) and >99% conversion was noted within 30-60 min with high turnover frequencies (TOF) at low catalyst loading (0.1 mol%). The catalyst could be easily separated out from the reaction mixture via centrifugation and was recyclable over several cycles, retaining its porous structure.

Direct Synthesis of Structurally Divergent Indole Alkaloids from Simple Chemicals

A direct and structurally divergent synthesis of indole alkaloids from very simple 2-vinylanilines, alkynes and TBN via a novel substrate fragmentation/cycloaddition strategy has been developed, which provides an efficient noble-metal-free approach to access a library of highly valuable indole derivatives of tryptamines and tryptamine-related oximes, lactams, and lactones, as well as β-carbolines, spiroindolines, and hexa-hydropyrrolo[2,3-b]indoles.

MK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

NOVEL ANTIVIRAL COMPOUNDS

The present invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing a viral infection such as HIV using the same.

Selective activation of enantiotopic C(sp3)-hydrogen by means of chiral phosphoric acid: Asymmetric synthesis of tetrahydroquinoline derivatives

Chiral phosphoric acid-catalyzed asymmetric C-H functionalization has been achieved. In this process, enantiotopic C(sp3)-hydrogen is selectively activated by chiral phosphoric acid to afford tetrahydroquinoline derivatives with excellent enantioselectivities (up to 97% ee).

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula (I): wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula (I): wherein c, X, Y, R2, R4 and R5 are defined herein, are useful as inhibitors of HIV replication.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

The present invention relates to compounds of formula (I) wherein c, X, Y, R2, R3, R4 and R6 are as defined herein, compositions and uses thereof for treating human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HIV infection

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula I : wherein c, R2, R3, R4, R5, R6, R7 and R8 are defined herein, are useful as inhibitors of HIV replication.